Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697365 | 0.76 | HSD11B1 (0.33) | LMNAHSD11B1ALDH1A1MEN1KMT2A | |
| SCHEMBL2960096 | 0.69 | HSD11B1 (0.53) | HSD11B1MEN1KMT2A | |
| SCHEMBL409092 | 0.68 | LMNA (0.53) | LMNAALDH1A1KDM4EADRA2AADRA1A | |
| SCHEMBL30207417 | 0.66 | LMNA (0.50) | LMNAALDH1A1KDM4EADRA2AADRA1A | |
| SCHEMBL18923150 | 0.65 | EPHX2 (0.50) | LMNAALDH1A1EPHX2KDM4EHTT | |
| SCHEMBL2964561 | 0.65 | CYP2C9 (0.31) | HSD11B1 | |
| SCHEMBL11357571 | 0.65 | ACE (0.46) | LMNAALDH1A1ADRA2AADRA1A | |
| SCHEMBL108335 | 0.64 | NPC1 (0.49) | LMNAALDH1A1ADRA2AADRA1A | |
| Ammonia Solution, Strong SCHEMBL11412539 | 0.64 | LMNA (0.47) | LMNAALDH1A1KDM4EADRA2AADRA1A | |
| SCHEMBL3388290 | 0.64 | LMNA (0.47) | LMNAALDH1A1ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1603933-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | NITROMED, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004098538-A2 | NITROSATED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | ADRB1, ADRB3, ADRA1D | LMNA 3062/4885HSD11B1 823/4885ALDH1A1 628/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | LMNA 3073/4885HSD11B1 941/4885ALDH1A1 610/4885 |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | LMNA 3927/4885HSD11B1 740/4885ALDH1A1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.